The Role of Aspirin after the TWILIGHT-ACS

This analysis corroborates the potential benefit of ticagrelor monotherapy following a short period of dual antiaggregation (DAPT) in patients with acute coronary syndrome (ACS).

ticagrelor vs. aspirina

This benefit consists of a significant bleeding reduction (3.6% vs. 7.6%, P < 0.001), without compromising ischemic events (4.3% vs. 4.4%, P = 0.84).

The latter, however, could be seen as excessive simplification of the clinical condition and, in this regard, multiple variables call for further discussion. 

DAPT Duration 

The GLOBAL-LEADERS is the sole study that published the benefit of discontinuing aspirin one month after PCI, even in an acute context such as STEMI.  

Despite the significant ischemic risk, reducing bleeding events by half did not come at a high cost. These outcomes are similar to the TICO outcomes.  


Read also: Anosmia 1 Year After a COVID-19 Diagnosis.


Minimizing bleeding is an appealing strategy that can be taken to extremes thanks to the advantages brought by new generation DES. One month of aspirin might be enough, or might not even be necessary, but adopting this therapeutic behavior requires further specific research. 

One Size Fits All? 

We should bear in mind that a large part of the Asian population in this cohort has acute coronary syndrome. 

Even though ethnicity is not included within the criteria for high bleeding risk, we are well aware that the Asian population has different mean body mass index and platelet reactivity compared against the western population. 

The evidence in favor of ticagrelor monotherapy after PCI piles up even though the right time to discontinue aspirin remains unclear, as does its potential benefits according to subgroups. 

Original Title: Ticagrelor monotherapy following percutaneous coronary intervention for acute coronary syndrome in TWILIGHT patients: still a future for aspirin?

Reference: Mattia Lunardi et al. Eur Heart J. 2021 Jul 15;42(27):2708-2709. doi: 10.1093/eurheartj/ehab037.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...